Latest news with #CRC
Yahoo
a day ago
- Business
- Yahoo
Natera to Present Clinical and Economic Utility of Signatera at ESMO GI, Highlights Innovations in MRD
AUSTIN, Texas, July 01, 2025--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, announced new data that will be presented at the 2025 European Society for Medical Oncology GI Congress (ESMO GI) in Barcelona, Spain. These presentations reinforce the strong clinical and economic utility of Signatera™ monitoring across colon and rectal cancers (CRC), as well as new clinical validation data on its tissue-free MRD assay. Signatera in CRC surveillance Data on >3,000 CRC patients will be shared in an oral presentation, concluding that adding Signatera ctDNA* monitoring to the current standard of care in surveillance can better identify patients who are candidates for metastasis-directed therapy (MDT). Results indicated that Signatera-positive patients were up to 20x more likely to receive curative-intent MDT than Signatera-negative patients. By comparison, CEA positivity led to only a 2x increase, with no added value in stage IV. Signatera Genome in rectal cancer An analysis will be presented from the MD Anderson INTERCEPT study (n=31) that used serial Signatera Genome testing in patients with locally advanced rectal cancer after neoadjuvant therapy. Results demonstrated 100% specificity/PPV, with surveillance sensitivity of 100% in the surgical cohort and 88% (7/8) overall. Economic utility of Signatera-guided therapy in adjuvant CRC A budget impact model from BUPA, a multinational health insurance provider with over 60 million customers, will outline a 43% expected reduction in healthcare costs using Signatera-guided adjuvant treatment versus standard of care in stage II-III CRC. "We're excited to present these new findings that continue to support the utility of Natera's products across GI cancers," said Adham Jurdi, M.D., senior medical director of oncology at Natera. "These data highlight our commitment to improving outcomes and driving innovation in MRD detection." Full list of data featuring Natera's technology at ESMO GI: July 4, 16:40-16:50 CET | FPN: 20 | Signatera (Oral Presentation)Presenter: Arvind Dasari, M.D., MSClinical utility of including circulating tumor DNA (ctDNA) monitoring in standard of care (SoC) colorectal cancer (CRC) surveillance July 4, 16:50-17:00 CET | FPN: 30 | Signatera (Oral Presentation)Presenter: Hideaki Bando, of ctDNA Clearance with Disease-Free Survival and Safety and Quality of Life from ctDNA-Directed Therapy: Findings from the ALTAIR Study July 4, 15:30-16:30 CET | FPN: 102P | Signatera (Poster Presentation)Presenter: Christos Mikropoulos, MBBS, MSc, M.D. (Res), MRCP, FRCRDirect cost of healthcare analysis of Signatera ctDNA testing in the adjuvant setting for a hypothetical cohort of stage II and stage III colorectal cancer (CRC) patients: a UK private payer perspective July 4, 15:30-16:30 CET | FPN: 243P | Signatera Genome (Poster Presentation)Presenter: Arvind Dasari, M.D., MSClinical performance of Signatera Genome assay in a sub-cohort of locally advanced rectal cancer (LARC) patients (pts) in the MD Anderson INTERCEPT program July 4, 15:30-16:30 CET | FPN: 93P | Tissue-free MRD (Poster Presentation)Presenter: Yoshiaki Nakamura, M.D., validation of a methylation-based, tissue-free colorectal cancer test for the detection of molecular residual disease by circulating tumor DNA July 4, 15:30-16:30 CET | FPN: 89P | Early Cancer Detection (Poster Presentation)Presenter: John P.Y. Shen, of methylation-based biomarkers to predict metastases, treatment effect, and microsatellite status in colorectal cancer Notes*Circulating tumor DNA About Natera Natera™ is a global leader in cell-free DNA and genetic testing, dedicated to oncology, women's health, and organ health. We aim to make personalized genetic testing and diagnostics part of the standard-of-care to protect health and inform earlier, more targeted interventions that help lead to longer, healthier lives. Natera's tests are supported by more than 300 peer-reviewed publications that demonstrate excellent performance. Natera operates ISO 13485-certified and CAP-accredited laboratories certified under the Clinical Laboratory Improvement Amendments (CLIA) in Austin, Texas, and San Carlos, California. For more information, visit Forward-Looking Statements All statements other than statements of historical facts contained in this press release are forward-looking statements and are not a representation that Natera's plans, estimates, or expectations will be achieved. These forward-looking statements represent Natera's expectations as of the date of this press release, and Natera disclaims any obligation to update the forward-looking statements. These forward-looking statements are subject to known and unknown risks and uncertainties that may cause actual results to differ materially, including with respect to whether the results of clinical or other studies will support the use of our product offerings, the impact of results of such studies, our expectations of the reliability, accuracy and performance of our tests, or of the benefits of our tests and product offerings to patients, providers and payers. Additional risks and uncertainties are discussed in greater detail in "Risk Factors" in Natera's recent filings on Forms 10-K and 10-Q and in other filings Natera makes with the SEC from time to time. These documents are available at and View source version on Contacts Investor Relations: Mike Brophy, CFO, Natera, Inc., investor@ Media: Lesley Bogdanow, VP of Corporate Communications, Natera, Inc., pr@ Sign in to access your portfolio
Business Wire
a day ago
- Business
- Business Wire
Natera to Present Clinical and Economic Utility of Signatera at ESMO GI, Highlights Innovations in MRD
AUSTIN, Texas--(BUSINESS WIRE)-- Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, announced new data that will be presented at the 2025 European Society for Medical Oncology GI Congress (ESMO GI) in Barcelona, Spain. These presentations reinforce the strong clinical and economic utility of Signatera™ monitoring across colon and rectal cancers (CRC), as well as new clinical validation data on its tissue-free MRD assay. Signatera in CRC surveillance Data on >3,000 CRC patients will be shared in an oral presentation, concluding that adding Signatera ctDNA * monitoring to the current standard of care in surveillance can better identify patients who are candidates for metastasis-directed therapy (MDT). Results indicated that Signatera-positive patients were up to 20x more likely to receive curative-intent MDT than Signatera-negative patients. By comparison, CEA positivity led to only a 2x increase, with no added value in stage IV. Signatera Genome in rectal cancer An analysis will be presented from the MD Anderson INTERCEPT study (n=31) that used serial Signatera Genome testing in patients with locally advanced rectal cancer after neoadjuvant therapy. Results demonstrated 100% specificity/PPV, with surveillance sensitivity of 100% in the surgical cohort and 88% (7/8) overall. Economic utility of Signatera-guided therapy in adjuvant CRC A budget impact model from BUPA, a multinational health insurance provider with over 60 million customers, will outline a 43% expected reduction in healthcare costs using Signatera-guided adjuvant treatment versus standard of care in stage II-III CRC. 'We're excited to present these new findings that continue to support the utility of Natera's products across GI cancers,' said Adham Jurdi, M.D., senior medical director of oncology at Natera. 'These data highlight our commitment to improving outcomes and driving innovation in MRD detection.' Full list of data featuring Natera's technology at ESMO GI: July 4, 16:40-16:50 CET | FPN: 20 | Signatera (Oral Presentation) Presenter: Arvind Dasari, M.D., MS Clinical utility of including circulating tumor DNA (ctDNA) monitoring in standard of care (SoC) colorectal cancer (CRC) surveillance July 4, 16:50-17:00 CET | FPN: 30 | Signatera (Oral Presentation) Presenter: Hideaki Bando, M.D. Association of ctDNA Clearance with Disease-Free Survival and Safety and Quality of Life from ctDNA-Directed Therapy: Findings from the ALTAIR Study July 4, 15:30-16:30 CET | FPN: 102P | Signatera (Poster Presentation) Presenter: Christos Mikropoulos, MBBS, MSc, M.D. (Res), MRCP, FRCR Direct cost of healthcare analysis of Signatera ctDNA testing in the adjuvant setting for a hypothetical cohort of stage II and stage III colorectal cancer (CRC) patients: a UK private payer perspective July 4, 15:30-16:30 CET | FPN: 243P | Signatera Genome (Poster Presentation) Presenter: Arvind Dasari, M.D., MS Clinical performance of Signatera Genome assay in a sub-cohort of locally advanced rectal cancer (LARC) patients (pts) in the MD Anderson INTERCEPT program July 4, 15:30-16:30 CET | FPN: 93P | Tissue-free MRD (Poster Presentation) Presenter: Yoshiaki Nakamura, M.D., Ph.D. Clinical validation of a methylation-based, tissue-free colorectal cancer test for the detection of molecular residual disease by circulating tumor DNA July 4, 15:30-16:30 CET | FPN: 89P | Early Cancer Detection (Poster Presentation) Presenter: John P.Y. Shen, M.D. Development of methylation-based biomarkers to predict metastases, treatment effect, and microsatellite status in colorectal cancer Notes * Circulating tumor DNA About Natera Natera™ is a global leader in cell-free DNA and genetic testing, dedicated to oncology, women's health, and organ health. We aim to make personalized genetic testing and diagnostics part of the standard-of-care to protect health and inform earlier, more targeted interventions that help lead to longer, healthier lives. Natera's tests are supported by more than 300 peer-reviewed publications that demonstrate excellent performance. Natera operates ISO 13485-certified and CAP-accredited laboratories certified under the Clinical Laboratory Improvement Amendments (CLIA) in Austin, Texas, and San Carlos, California. For more information, visit Forward-Looking Statements All statements other than statements of historical facts contained in this press release are forward-looking statements and are not a representation that Natera's plans, estimates, or expectations will be achieved. These forward-looking statements represent Natera's expectations as of the date of this press release, and Natera disclaims any obligation to update the forward-looking statements. These forward-looking statements are subject to known and unknown risks and uncertainties that may cause actual results to differ materially, including with respect to whether the results of clinical or other studies will support the use of our product offerings, the impact of results of such studies, our expectations of the reliability, accuracy and performance of our tests, or of the benefits of our tests and product offerings to patients, providers and payers. Additional risks and uncertainties are discussed in greater detail in 'Risk Factors' in Natera's recent filings on Forms 10-K and 10-Q and in other filings Natera makes with the SEC from time to time. These documents are available at and
Indian Express
a day ago
- Indian Express
How handling of minors in conflict with law by police has evolved over decades
In the Netflix miniseries Adolescence, a 13-year-old boy accused of the murder of a girl in his class is questioned by the police in the presence of his father and solicitor. Later, a psychologist works with him at the youth detention facility to prepare a pre-trial report on his mental capacity. Over the past few decades, especially following the UN Convention on the Rights of the Child (CRC) signed in 1989 – of which India is a signatory – there has been a higher level of sensitivity when it comes to dealing with minors in conflict with law. 'In all actions concerning children, whether undertaken by public or private social welfare institutions, courts of law, administrative authorities or legislative bodies, the best interests of the child shall be a primary consideration,' the Convention states. In the incident that took place along the eastern suburbs of the city last week where a 16-year-old male allegedly pushed his 15-year-old friend, a female, from atop the terrace of a 32-storeyed building, the Mumbai Police that suspected something amiss in his statement spoke to the 16-year-old in the presence of his father. The boy had initially told the police that the girl had been under academic stress and hence had died by suicide and he had nothing to do with it. 'The version of events he gave was not adding up. Since he is a minor, as per the Juvenile Justice Act, we asked his father to be present when we questioned him regarding the inconsistencies in his statement. The tone of questioning is much different from usual cases and we tried to take his father's help to arrive at the truth,' an official said. While the police registered an FIR in the case on Monday, they sent the boy home to his parents and produced him before the Dongri Observation home in line with the JJ Act. An officer said that usually when they are questioning a minor, it is done in the presence of someone they are comfortable with. 'Usually, we get a woman officer to question minors. If they are too nervous, we also go to the residence of the minor and do not wear a uniform so that the minor is more at ease to talk,' the officer said. The officer added, 'Initially, we just conduct basic enquiry. The actual statement of the minor is taken in the presence of a Probation Officer appointed in the case by the Children Welfare Committee (CWC) where the child is comfortable.' Section 10 of the JJ Act that deals with Apprehension of child alleged to be in conflict with law mentions, ' ..in no case, a child alleged to be in conflict with law shall be placed in a police lockup or lodged in a jail….The State Government shall make rules consistent with this Act,—(i) to provide for persons through whom (including registered voluntary or non-governmental organisations) any child alleged to be in conflict with law may be produced before the Board..' The JJ Act further provides details about various aspects in dealing with a juvenile in conflict with law from the role of a person in whose charge a child in conflict with law is to be placed to bail to the role of parents and probation officers. While under the JJ Act 2000, punishment awarded to juveniles in conflict is law was lesser as compared to adults, the amended JJ Act 2015, allows for juveniles in conflict with law in the 16-18 age group to be tried as adults in case of heinous crimes following the approval of the court.
Time of India
3 days ago
- Politics
- Time of India
Activist and writer KM Salimkumar dies
Kochi: Dalit thinker, writer and activist K M Salimkumar passed away at Indira Gandhi Co-operative Hospital, Kadavanthra, Ernakulam, on Sunday. He was 76. Born on March 10, 1949, in Velliyamattom panchayat, Idukki, Salimkumar studied at several institutions, including Maharaja's College, Ernakulam, where he became associated with the Naxalite movement in 1969. He later worked with the CRC and CPI (ML) for nearly two decades and was imprisoned for 17 months during the Emergency. A turning point came in 1989 when he publicly burned the Manusmriti in Vaikom, marking his shift towards organized dalit activism. He went on to play leading roles in organizations like Adhasthitha Navodhana Munnani, Dalit Aikya Samithi and Kerala Dalit Mahasabha. Salimkumar was a powerful voice in dalit literature, editing journals like Raktha Pathaka and Dalit Aikya Shabdam. His major works include Samvarnavum Samavayathinte Rashtreeyavum, Negritude, Ithanu Hindu Fascism and Vamsamedhavithvathinte Sookshmathalangal. His autobiography Kadutha is set to be published soon. He leaves behind sons Dr P S Bhagat and P S Budha and grandchildren. His wife Anandavalli predeceased him.
CBS News
7 days ago
- General
- CBS News
Recreation center in Schaumburg, Illinois, closed until further notice after fire
The Meineke Recreation Center in Schaumburg, Illinois, will remain closed until further notice after a fire nearby earlier this week. A construction crew hit a gas line in the 200-block of East Weathersfield Way Monday around 11 a.m., causing a fire. The recreation center and its outdoor pool were both evacuated. The fire was contained to the construction site and no injuries were reported, village officials said. NICOR was called to the scene to shut off the gas and the road was closed for hours during the response and investigation. The Schaumburg Park District said as of Wednesday, it was still working to restore critical systems and ensure the facility is safe. The Meineke Pool at the recreation center will also remain closed until further notice. Members of the Meineke Recreation Center may use the CRC and the Schaumburg Tennis Plus facilities.
